SELLAS Life Sciences Group, Inc. (SLS)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (7.1M) | (8.3M) | (9.3M) | (10.6M) |
| Net Income | (6.8M) | (7.7M) | (8.4M) | (9.6M) |
| Diluted EPS | $-0.06 | N/A | $-0.05 | $-0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.0M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 900K | 0.00 | ||
| Operating Income | (31.9M) | (37.9M) | (31.5M) | (28.3M) |
| Net Income | (41.3M) | (37.3M) | (30.9M) | (26.9M) |
| Diluted EPS | $-2.13 | $-1.34 | $-0.50 | $-0.25 |